127 related articles for article (PubMed ID: 17303424)
1. Ascorbic acid inhibits PMP22 expression by reducing cAMP levels.
Kaya F; Belin S; Bourgeois P; Micaleff J; Blin O; Fontés M
Neuromuscul Disord; 2007 Mar; 17(3):248-53. PubMed ID: 17303424
[TBL] [Abstract][Full Text] [Related]
2. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease.
Passage E; Norreel JC; Noack-Fraissignes P; Sanguedolce V; Pizant J; Thirion X; Robaglia-Schlupp A; Pellissier JF; Fontés M
Nat Med; 2004 Apr; 10(4):396-401. PubMed ID: 15034573
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the benefits of vitamin cocktails in treating Charcot-Marie-Tooth disease type 1A.
Kaya F; Belin S; Micallef J; Blin O; Fontés M
Muscle Nerve; 2008 Aug; 38(2):1052-4. PubMed ID: 18663735
[TBL] [Abstract][Full Text] [Related]
4. The alpha-chemokine CXCL14 is up-regulated in the sciatic nerve of a mouse model of Charcot-Marie-Tooth disease type 1A and alters myelin gene expression in cultured Schwann cells.
Barbaria EM; Kohl B; Buhren BA; Hasenpusch-Theil K; Kruse F; Küry P; Martini R; Müller HW
Neurobiol Dis; 2009 Mar; 33(3):448-58. PubMed ID: 19111616
[TBL] [Abstract][Full Text] [Related]
5. Ascorbic acid is a regulator of the intracellular cAMP concentration: old molecule, new functions?
Kaya F; Belin S; Diamantidis G; Fontes M
FEBS Lett; 2008 Oct; 582(25-26):3614-8. PubMed ID: 18835269
[TBL] [Abstract][Full Text] [Related]
6. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy.
Meyer zu Horste G; Prukop T; Liebetanz D; Mobius W; Nave KA; Sereda MW
Ann Neurol; 2007 Jan; 61(1):61-72. PubMed ID: 17262851
[TBL] [Abstract][Full Text] [Related]
7. An 8.5-kb segment of the PMP22 promoter responds to loss of axon signals during Wallerian degeneration, but does not respond to specific axonal signals during nerve regeneration.
Orfali W; Nicholson RN; Guiot MC; Peterson AC; Snipes GJ
J Neurosci Res; 2005 Apr; 80(1):37-46. PubMed ID: 15723356
[TBL] [Abstract][Full Text] [Related]
8. A derivative of ascorbic acid modulates cAMP production.
Bordignon B; Mones S; Rahman F; Chiron J; Peiretti F; Vidal N; Fontes M
Biochem Biophys Res Commun; 2013 Sep; 439(1):137-41. PubMed ID: 23942115
[TBL] [Abstract][Full Text] [Related]
9. Expression profiling of sciatic nerve in a Charcot-Marie-Tooth disease type 1a mouse model.
ten Asbroek AL; Verhamme C; van Groenigen M; Wolterman R; de Kok-Nazaruk MM; Baas F
J Neurosci Res; 2005 Mar; 79(6):825-35. PubMed ID: 15672449
[TBL] [Abstract][Full Text] [Related]
10. Expression pattern of the peripheral myelin protein 22kDa (PMP22) in neural and non-neural tissue types of adult wildtype and Trembler mice--a comparative study.
Rautenstrauss B; Zechner U; Hameister H; Grehl H; Liehr T
J Peripher Nerv Syst; 1998; 3(2):117-24. PubMed ID: 10959245
[TBL] [Abstract][Full Text] [Related]
11. Impairment of PMP22 transgenic Schwann cells differentiation in culture: implications for Charcot-Marie-Tooth type 1A disease.
Nobbio L; Vigo T; Abbruzzese M; Levi G; Brancolini C; Mantero S; Grandis M; Benedetti L; Mancardi G; Schenone A
Neurobiol Dis; 2004 Jun; 16(1):263-73. PubMed ID: 15207283
[TBL] [Abstract][Full Text] [Related]
12. Distinct disease mechanisms in peripheral neuropathies due to altered peripheral myelin protein 22 gene dosage or a Pmp22 point mutation.
Giambonini-Brugnoli G; Buchstaller J; Sommer L; Suter U; Mantei N
Neurobiol Dis; 2005 Apr; 18(3):656-68. PubMed ID: 15755691
[TBL] [Abstract][Full Text] [Related]
13. Molecular alterations resulting from frameshift mutations in peripheral myelin protein 22: implications for neuropathy severity.
Johnson JS; Roux KJ; Fletcher BS; Fortun J; Notterpek L
J Neurosci Res; 2005 Dec; 82(6):743-52. PubMed ID: 16273544
[TBL] [Abstract][Full Text] [Related]
14. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial.
Burns J; Ouvrier RA; Yiu EM; Joseph PD; Kornberg AJ; Fahey MC; Ryan MM
Lancet Neurol; 2009 Jun; 8(6):537-44. PubMed ID: 19427269
[TBL] [Abstract][Full Text] [Related]
15. [Charcot-Marie-Tooth disease].
Lee YC; Chang MH; Lin KP
Acta Neurol Taiwan; 2008 Sep; 17(3):203-13. PubMed ID: 18975529
[TBL] [Abstract][Full Text] [Related]
16. Sex-dimorphic effects of progesterone and its reduced metabolites on gene expression of myelin proteins by rat Schwann cells.
Magnaghi V; Veiga S; Ballabio M; Gonzalez LC; Garcia-Segura LM; Melcangi RC
J Peripher Nerv Syst; 2006 Jun; 11(2):111-8. PubMed ID: 16787508
[TBL] [Abstract][Full Text] [Related]
17. [Detection of duplications or deletions of the PMP22 gene using real-time quantitative PCR].
Zhang FF; Tang BS; Shen Y; Zhao GH; Xia K; Zhao YQ; Chen B; Zhang C; Pan Q; Cai F; Liu XM; Luo W; Zhang RX; Guo P
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Oct; 22(5):537-40. PubMed ID: 16215943
[TBL] [Abstract][Full Text] [Related]
18. Dichloroacetate causes reversible demyelination in vitro: potential mechanism for its neuropathic effect.
Felitsyn N; Stacpoole PW; Notterpek L
J Neurochem; 2007 Jan; 100(2):429-36. PubMed ID: 17241159
[TBL] [Abstract][Full Text] [Related]
19. Alterations in degradative pathways and protein aggregation in a neuropathy model based on PMP22 overexpression.
Fortun J; Go JC; Li J; Amici SA; Dunn WA; Notterpek L
Neurobiol Dis; 2006 Apr; 22(1):153-64. PubMed ID: 16326107
[TBL] [Abstract][Full Text] [Related]
20. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial.
Pareyson D; Reilly MM; Schenone A; Fabrizi GM; Cavallaro T; Santoro L; Vita G; Quattrone A; Padua L; Gemignani F; Visioli F; Laurà M; Radice D; Calabrese D; Hughes RA; Solari A; ;
Lancet Neurol; 2011 Apr; 10(4):320-8. PubMed ID: 21393063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
